Cheryl Doreen Zimberlin
Director/Board Member at Outrun Therapeutics Ltd.
Network origin in Cheryl Doreen Zimberlin first degree
Entity | Entity type | Industry | |
---|---|---|---|
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Cheryl Doreen Zimberlin via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Biotechnology | Director/Board Member | |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
PROGYNY, INC. | Miscellaneous Commercial Services | Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investment Managers | Private Equity Investor | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member | |
University College London | College/University | Undergraduate Degree | |
University of London | College/University | Doctorate Degree | |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Biotechnology | Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
United Kingdom | 7 |
United States | 5 |
Netherlands | 4 |
Switzerland | 3 |
Finland | 2 |
Sectoral
Health Technology | 11 |
Finance | 4 |
Commercial Services | 3 |
Consumer Services | 3 |
Operational
Director/Board Member | 17 |
Private Equity Investor | 2 |
Private Equity Analyst | 1 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Most connected contacts
- Stock Market
- Insiders
- Cheryl Doreen Zimberlin
- Company connections